Early trial results indicate COVID-19 vaccine is immunogenic and safe
- Posted on: Sep 9 2020
- Leave a response
The authors conducted a phase 1, dose-escalation, open-label clinical trial designed to determine the safety, reactogenicity and immunogenicity of an mRNA vaccine against SARS-CoV-2.
Source: AAO
Posted in: Uncategorized
